|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||29.40 - 31.78|
|52-week range||10.28 - 70.00|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||64.67|
CAMBRIDGE, Mass., Jun 18, 2021--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN
CAMBRIDGE, Mass., Jun 11, 2021--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.
Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.